Literature DB >> 3013763

Polymorphisms within the HLA-DR3 haplotypes. I. HLA-DR polymorphisms detected at the protein and DNA levels are reflected by T-cell recognition.

R Bontrop, M Tilanus, M Mikulski, M van Eggermond, A Termijtelen, M Giphart.   

Abstract

HLA-DR molecules were isolated from eight different HLA-DR3 homozygous B-cell lines by immunoprecipitation with monoclonal antibodies, and they were subsequently analyzed by two-dimensional gel electrophoresis. We found that HLA-DR3 homozygous B-cell lines of consanguineous origin express two types of HLA-DR molecules. One type of HLA-DR molecule was present in all the cell lines tested, whereas the second DR molecule appears to be polymorphic. DNA isolated from the different HLA-DR3 homozygous cell lines was studied by Southern blot analysis to determine whether any DR beta restriction fragment length polymorphism could be observed. Polymorphisms detected at both the product and genomic level have been compared to each other, and their relations to the serological (HLA-DR) and cellular (HLA-D and LB-Q1) typing data will be discussed.

Mesh:

Substances:

Year:  1986        PMID: 3013763     DOI: 10.1007/bf00372674

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  32 in total

1.  Divergent and invariant HLA class II beta chain isoelectric points.

Authors:  R Bontrop; R van Miltenburg; F Koning; R Gerrets; C Hyland; M Giphart
Journal:  Hum Immunol       Date:  1986-05       Impact factor: 2.850

2.  Quantitative and qualitative differences in HLA-DR molecules correlated with antigen-presentation capacity.

Authors:  R Bontrop; T Ottenhoff; R Van Miltenburg; D Elferink; R De Vries; M Giphart
Journal:  Eur J Immunol       Date:  1986-02       Impact factor: 5.532

3.  Structural organization of the DR subregion of the human major histocompatibility complex.

Authors:  T Spies; R Sorrentino; J M Boss; K Okada; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

4.  Characterization of an HLA DR beta pseudogene.

Authors:  D Larhammar; B Servenius; L Rask; P A Peterson
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

5.  A mouse monoclonal antibody detecting a DR-related MT2-like specificity: serology and biochemistry.

Authors:  F Koning; I Schreuder; M Giphart; H Bruning
Journal:  Hum Immunol       Date:  1984-04       Impact factor: 2.850

6.  Immunology. Molecular biology of the major histocompatibility complex.

Authors:  J Lee; J Trowsdale
Journal:  Nature       Date:  1983 Jul 21-27       Impact factor: 49.962

7.  Autoimmune human T lymphocytes specific for acetylcholine receptor.

Authors:  R Hohlfeld; K V Toyka; K Heininger; H Grosse-Wilde; I Kalies
Journal:  Nature       Date:  1984 Jul 19-25       Impact factor: 49.962

8.  Demonstration of two distinct light chains in HLA-DR-associated antigens by two-dimensional gel electrophoresis.

Authors:  T A de Kretser; M J Crumpton; J G Bodmer; W F Bodmer
Journal:  Eur J Immunol       Date:  1982-03       Impact factor: 5.532

9.  Complete sequence of an HLA-dR beta chain deduced from a cDNA clone and identification of multiple non-allelic DR beta chain genes.

Authors:  E O Long; C T Wake; J Gorski; B Mach
Journal:  EMBO J       Date:  1983       Impact factor: 11.598

10.  Dw/LD-related molecular polymorphism of DR4 beta-chains.

Authors:  J P Groner; A J Watson; F H Bach
Journal:  J Exp Med       Date:  1983-05-01       Impact factor: 14.307

View more
  11 in total

1.  Serological recognition of HLA-DR allodeterminant corresponding to DNA sequence involved in gene conversion.

Authors:  C C Berte; N Tanigaki; R Tosi; J Gorski; B Mach
Journal:  Immunogenetics       Date:  1988       Impact factor: 2.846

2.  DNA typing of an HLA-DR bilocus specificity by gene amplification and oligonucleotide hybridization.

Authors:  R Sorrentino; C Iannicola; S Botti; S Costanzi; N Tanigaki; R Tosi
Journal:  Immunogenetics       Date:  1989       Impact factor: 2.846

3.  Polymorphism and complexity of HLA-DR: evidence for intra-HLA-DR region crossing-over events.

Authors:  R E Bontrop; M G Tilanus; M M Mikulski; D G Elferink; A Termijtelen; R R de Vries; J J van Rood; M J Giphart
Journal:  Immunogenetics       Date:  1988       Impact factor: 2.846

4.  Biochemically defined polymorphism of bovine MHC class II antigens.

Authors:  I Joosten; M F Sanders; A van der Poel; J L Williams; B G Hepkema; E J Hensen
Journal:  Immunogenetics       Date:  1989       Impact factor: 2.846

5.  The two-dimensional migration pattern of the single HLA-DR beta chain expressed in DRw8 haplotypes is not fully predictive of its activity in antigen presentation.

Authors:  M Bouillot; J Choppin; G Sterkers; C Freidel; L Gebuhrer; H Betuel; J P Levy
Journal:  Immunogenetics       Date:  1988       Impact factor: 2.846

6.  Molecular analysis distinguishes two HLA-DR3-bearing major histocompatibility complex extended haplotypes.

Authors:  M Z Wescott; Z L Awdeh; E J Yunis; C A Alper
Journal:  Immunogenetics       Date:  1987       Impact factor: 2.846

7.  Arg74 in HLA-DRB1 and DRB3 controls a DR3-related epitope.

Authors:  R Sorrentino; C Iannicola; S Costanzi; G Ratti; C Hurley; R Tosi; N Tanigaki
Journal:  Immunogenetics       Date:  1990       Impact factor: 2.846

8.  HLA association with dermatitis herpetiformis is accounted for by a cis or transassociated DQ heterodimer.

Authors:  M A Hall; J S Lanchbury; W J Bolsover; K I Welsh; P J Ciclitira
Journal:  Gut       Date:  1991-05       Impact factor: 23.059

9.  The chimpanzee major histocompatibility complex class II DR subregion contains an unexpectedly high number of beta-chain genes.

Authors:  R E Bontrop; L A Broos; K Pham; R M Bakas; N Otting; M Jonker
Journal:  Immunogenetics       Date:  1990       Impact factor: 2.846

10.  Major histocompatibility complex class II-restricted antigen presentation across a species barrier: conservation of restriction determinants in evolution.

Authors:  R E Bontrop; D G Elferink; N Otting; M Jonker; R R de Vries
Journal:  J Exp Med       Date:  1990-07-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.